Search alternatives:
significant adverse » significant advantage (Expand Search), significant decrease (Expand Search)
adverse decrease » rivers decreased (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
significant adverse » significant advantage (Expand Search), significant decrease (Expand Search)
adverse decrease » rivers decreased (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
S1 File -
Published 2024“…Compared with the GA group, the VAS scores at 6 hours, 12 hours, and 24 hours after surgery in the TAP+GA group were significantly decreased, and the intraoperative consumption of remifentanil and the numbers of postoperative analgesic pump presses were significantly reduced (<i>P</i><0.05). …”
-
9
The flow chart of the study.
Published 2024“…Compared with the GA group, the VAS scores at 6 hours, 12 hours, and 24 hours after surgery in the TAP+GA group were significantly decreased, and the intraoperative consumption of remifentanil and the numbers of postoperative analgesic pump presses were significantly reduced (<i>P</i><0.05). …”
-
10
The Laboratory Animal Flow Diagram.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
11
<sup>1</sup>H NMR spectra for kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
12
<sup>13</sup>C NMR spectra for Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
13
The structures of T3 and Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
14
Synthesis process of Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
15
ESI-HRMS spectra for Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
16
-
17
-
18
-
19
-
20